Journal List > Cancer Res Treat > v.55(3) > 1516083285

TOOLS
Yoon, Kim, Hong, Kim, Kim, Kim, Yun, Yoo, Ahn, Kim, Lee, Kim, Park, Jeong, Cheon, Kim, Yun, Lim, Cha, Jang, Zang, Kim, Kang, and Kim: ERRATUM: Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group
Erratum

Cancer Res Treat 2023;55(3):1061-1061.

Published online: 21 April 2023

DOI: https://doi.org/10.4143/crt.2021.1115.E

ERRATUM: Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group

Shinkyo Yoon1, Miso Kim2, Yong Sang Hong1, Han Sang Kim3, Seung Tae Kim4, Jihun Kim5, Hongseok Yun6, Changhoon Yoo1, Hee Kyung Ahn7, Hyo Song Kim3, In Hee Lee8, In-Ho Kim9, Inkeun Park7, Jae Ho Jeong1, Jaekyung Cheon10, Jin Won Kim11, Jina Yun12, Sun Min Lim3, Yongjun Cha13, Se Jin Jang5, Dae Young Zang14, Tae Won Kim1, Jin Hyoung Kang9, Jee Hyun Kim11

1Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

2Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea

3Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea

4Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

5Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

6Department of Genomic Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea

7Division of Medical Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea

8Department of Oncology/Hematology, Kyungpook National University Chilgok Hospital, Daegu, Korea

9Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

10Department of Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea

11Division of Hematology/Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea

12Division of Medical Oncology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea

13Center for Colorectal Cancer, National Cancer Center, Research Institute and Hospital, Goyang, Korea

14Department of Internal Medicine, Hallym University Medical Center, Hallym University, Anyang, Korea

Copyright © 2023 by the Korean Cancer Association

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Correction to: Cancer Res Treat. 2022 Jan;54(1):1-9; DOI: https://doi.org/10.4143/crt.2021.1115
For the data represented in Table 2, we have corrected the level of evidence of K-CAT level 2 and 3. As the table shown, prospective phase I/II trials required for K-CAT level 2 include clinical trials across tumor types, such as basket trials. For the clinical benefit of specific cancer types, expert consensus is needed. K-CAT level 3A requires a retrospective study or case series with potential clinical benefit in s specific tumor types. K-CAT level 3B is revised from a retrospective study as clinical studies show potential clinical benefits in other indications. The corrected version of the table is below.

Table 2.
KPMNG scale of clinical actionability of molecular target (K-CAT)
Level Clinical implication Required level of evidence
1 Treatment should be considered standard of care MFDS, FDA, EMA or equivalent-approved drug OR
Prospective, randomized, phase III trials showing the benefit of survival endpoints
2 Treatment would be considered Prospective phase I/II trials show clinical benefita)
3 Clinical trials to be discussed with patients A: Retrospective study or case series show potential clinical benefit in a specific tumor type
B: Clinical studies show potential clinical benefit in other indications
4 Preclinical data only, lack of clinical data Preclinical evidence suggests the potential benefit
G Suspicious germline variant on tumor tissue NGS Suggestive actionable germline variant on tumor tissue testing
R Predictive biomarker of resistance FDA-recognized predictive biomarker of resistance

EMA, European Medicines Agency; FDA, U.S. Food and Drug Administration; K-CAT, KPMNG scale of Clinical Actionability of molecular Targets; KPMNG, Korean Precision Medicine Networking Group; MFDS, Ministry of Food and Drug Safety; NGS, next-generation sequencing.

a) Prospective phase I/II trials supporting level 2 targets include clinical trials across tumor types such as basket trials. In this case, the clinical benefit needs to be judged by expert consensus.

TOOLS
Similar articles